Features | VJOncology

Trastuzumab deruxtecan and the evolving HER2-low breast cancer landscape

VJOncology is excited to present the latest data and developments in the HER2-low breast cancer field, with comments from experts…

FDA approves combination therapy of tremelimumab, durvalumab, and platinum-based chemotherapy for metastatic NSCLC

The U.S. Food and Drug Administration (FDA) have approved tremelimumab in combination with durvalumab and platinum-based chemotherapy for metastatic non-small…

EMERALD: updated results on the impact of duration of prior CDK4/6i and FDA priority review

The U.S. Food and Drug Administration (FDA) has granted priority review for elacestrant, a selective estrogen receptor degrader (SERD), based…

Worse outcomes for immunosuppressed patients with cancer and COVID-19 treated with immunotherapy

A report published in JAMA Oncology suggests that cancer patients with baseline immunosuppression and COVID-19 experience worse outcomes and an…

Clinical breakthroughs in immunotherapy from SITC 2022

VJOncology are excited to highlight the latest in immuno-oncology from the 37th Annual Meeting of the Society for Immunotherapy in…

First-line maintenance with olaparib monotherapy and in combination bevacizumab increases survival in advanced ovarian cancer

Over 75% of patients with ovarian cancer are diagnosed at an advanced stage, as early-stage disease is usually asymptomatic.1,2 The…

TROPiCS-02: Overall survival benefit of sacituzumab govitecan in HR+/HER2- metastatic breast cancer

Antibody-drug conjugates (ADCs) are an emerging class of anticancer drugs consisting of a monoclonal antibody linked to a cytotoxic chemotherapy…

New research elucidates how air pollution causes lung cancer in never-smokers

Research presented at the European Society of Medical Oncology (ESMO) Congress 2022 has uncovered a non-mutagenic mechanism by which air…